91 related articles for article (PubMed ID: 24913258)
1. A Sclerostin super-producer cell line derived from the human cell line SaOS-2: a new tool for the study of the molecular mechanisms driving Sclerostin expression.
Pérez-Campo FM; Sañudo C; Delgado-Calle J; Arozamena J; Zarrabeitia MT; Riancho JA
Calcif Tissue Int; 2014 Aug; 95(2):194-9. PubMed ID: 24913258
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin expression is induced by BMPs in human Saos-2 osteosarcoma cells but not via direct effects on the sclerostin gene promoter or ECR5 element.
Yu L; van der Valk M; Cao J; Han CY; Juan T; Bass MB; Deshpande C; Damore MA; Stanton R; Babij P
Bone; 2011 Dec; 49(6):1131-40. PubMed ID: 21890009
[TBL] [Abstract][Full Text] [Related]
3. Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone, hypoxia, and prostaglandin E2.
Fujiwara M; Kubota T; Wang W; Ohata Y; Miura K; Kitaoka T; Okuzaki D; Namba N; Michigami T; Kitabatake Y; Ozono K
Bone; 2016 Apr; 85():91-8. PubMed ID: 26851122
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes.
Delgado-Calle J; Sañudo C; Bolado A; Fernández AF; Arozamena J; Pascual-Carra MA; Rodriguez-Rey JC; Fraga MF; Bonewald L; Riancho JA
J Bone Miner Res; 2012 Apr; 27(4):926-37. PubMed ID: 22162201
[TBL] [Abstract][Full Text] [Related]
5. 1α,25-dihydroxyvitamin D3 stimulates human SOST gene expression and sclerostin secretion.
Wijenayaka AR; Yang D; Prideaux M; Ito N; Kogawa M; Anderson PH; Morris HA; Solomon LB; Loots GG; Findlay DM; Atkins GJ
Mol Cell Endocrinol; 2015 Sep; 413():157-67. PubMed ID: 26112182
[TBL] [Abstract][Full Text] [Related]
6. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro.
Jäger A; Götz W; Lossdörfer S; Rath-Deschner B
J Periodontal Res; 2010 Apr; 45(2):246-54. PubMed ID: 19778325
[TBL] [Abstract][Full Text] [Related]
7. Rat Osteosarcoma Cells as a Therapeutic Target Model for Osteoregeneration via Sclerostin Knockdown.
Sedaghati B; Jahroomishirazi R; Starke A; Hacker MC; Schulz-Siegmund M
Cells Tissues Organs; 2016; 201(5):366-79. PubMed ID: 27233518
[TBL] [Abstract][Full Text] [Related]
8. SOST is a target gene for PTH in bone.
Keller H; Kneissel M
Bone; 2005 Aug; 37(2):148-58. PubMed ID: 15946907
[TBL] [Abstract][Full Text] [Related]
9. Sclerostin, an osteocytes-derived bone-forming inhibitor.
Włodarski KH; Galus R; Brodzikowska A; Włodarski PK
Pol Orthop Traumatol; 2013 Jul; 78():151-4. PubMed ID: 23820854
[TBL] [Abstract][Full Text] [Related]
10. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts.
Vincent C; Findlay DM; Welldon KJ; Wijenayaka AR; Zheng TS; Haynes DR; Fazzalari NL; Evdokiou A; Atkins GJ
J Bone Miner Res; 2009 Aug; 24(8):1434-49. PubMed ID: 19292615
[TBL] [Abstract][Full Text] [Related]
11. Low sirtuin 1 levels in human osteoarthritis subchondral osteoblasts lead to abnormal sclerostin expression which decreases Wnt/β-catenin activity.
Abed É; Couchourel D; Delalandre A; Duval N; Pelletier JP; Martel-Pelletier J; Lajeunesse D
Bone; 2014 Feb; 59():28-36. PubMed ID: 24184155
[TBL] [Abstract][Full Text] [Related]
12. Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells.
Delgado-Calle J; Arozamena J; Pérez-López J; Bolado-Carrancio A; Sañudo C; Agudo G; de la Vega R; Alonso MA; Rodríguez-Rey JC; Riancho JA
Mol Cell Endocrinol; 2013 Apr; 369(1-2):27-34. PubMed ID: 23415712
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin expression in skeletal sarcomas.
Shen J; Meyers CA; Shrestha S; Singh A; LaChaud G; Nguyen V; Asatrian G; Federman N; Bernthal N; Eilber FC; Dry SM; Ting K; Soo C; James AW
Hum Pathol; 2016 Dec; 58():24-34. PubMed ID: 27498059
[TBL] [Abstract][Full Text] [Related]
14. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
van Bezooijen RL; ten Dijke P; Papapoulos SE; Löwik CW
Cytokine Growth Factor Rev; 2005 Jun; 16(3):319-27. PubMed ID: 15869900
[TBL] [Abstract][Full Text] [Related]
15. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
van Bezooijen RL; Svensson JP; Eefting D; Visser A; van der Horst G; Karperien M; Quax PH; Vrieling H; Papapoulos SE; ten Dijke P; Löwik CW
J Bone Miner Res; 2007 Jan; 22(1):19-28. PubMed ID: 17032150
[TBL] [Abstract][Full Text] [Related]
16. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
17. Sost, independent of the non-coding enhancer ECR5, is required for bone mechanoadaptation.
Robling AG; Kang KS; Bullock WA; Foster WH; Murugesh D; Loots GG; Genetos DC
Bone; 2016 Nov; 92():180-188. PubMed ID: 27601226
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin is overexpressed by plasma cells from multiple myeloma patients.
Brunetti G; Oranger A; Mori G; Specchia G; Rinaldi E; Curci P; Zallone A; Rizzi R; Grano M; Colucci S
Ann N Y Acad Sci; 2011 Nov; 1237():19-23. PubMed ID: 22082361
[TBL] [Abstract][Full Text] [Related]
19. Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.
van Bezooijen RL; Papapoulos SE; Löwik CW
J Endocrinol Invest; 2005; 28(8 Suppl):15-7. PubMed ID: 16323824
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
